投资要点 核心逻辑：公司通过战略性收购行业领先的数字医疗平台春雨医生，从传统地产 与物管运营商向"物业+数字医疗"融合服务商转型。此举旨在应对地产周期压力， 构建弱周期性"第二增长曲线"，优化收入结构，提升盈利韧性及长期估值吸引力。 引入优质弱周期资产，优化结构与平滑业绩：本次收购以极具吸引力的价格（单 用户成本仅 1.5 元）获取了中国移动互联网医疗领域的优质资产，包括 1.8 亿注 册用户、69 万名签约医师及 4 亿份健康档案，同时获得医疗牌照（《医疗机构 执业许可证》及互联网医院资质）。公司地产主业（物管及投资物业）面临下行 周期压力，春雨医生业务具有轻资产、现金流稳定及非周期性特征，收购后预计 贡献总收入约 20%，可有效平滑公司整体业绩波动。 独特资源赋能，实现"1+1>2"的深度协同：公司独有的三大资源将为春雨医生解 决行业痛点、开拓增长空间，具体体现在地产场景资源赋能获客与服务、政府关 系资源赋能支付与 G 端市场、品牌信任资源赋能用户转化。 AI 技术构筑壁垒，重塑服务模式与成本结构：2023 年 5 月，基于大模型的 AI 医生产品春雨慧问推出，实现秒级响应的全流程 AI 赋能。AI 技术 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 國鋭生活有限公司 | | | 呈交日期: | 2026年2月3日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00108 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 3,219,373,986 0 3,219,373,986 增加 / 減少 (-) 0 本月底結存 3,219,373,986 0 3,219,373,986 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本 公 佈 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 任 何 證 券 之 邀 請 或 要 約。 GR LIFE STYLE COMPANY LIMITED 國銳生活有限公司 （於 香 港 註 冊 成 立 之 有 限 公 司） （股 份 代 號：108） 補充公佈 有關涉及根據特別授權 發行代價股份的建議收購目標公司 銷售股份的須予披露交易 茲提述國銳生活有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」）日期為 二零二五年十二月五日有關建議收購事項的公佈（「該公佈」）。除 非 另 有 界 定， 否 則 本 公 佈 所 用 詞 彙 與 該 公 佈 所 界 定 者 具 有 相 同 涵 義。本 公 佈 旨 在 提 供 有 關 建 議 收 購 事 項 的 進 一 步 資 料。 本 公 司 謹 此 就 建 議 收 ...

Major Events - Dongpeng Beverage (09980) will conduct its IPO from January 26 to January 29, with an expected listing date of February 3 [1] - Zijin Mining (02899) plans to acquire 100% of Allied Gold Corporation for approximately CAD 5.5 billion [2] - AsiaInfo Technologies (01675) collaborates with ABB Robotics to establish an "Embodied Intelligence Laboratory" [3] - Dongyang Sunshine Pharmaceutical (06887) signs a strategic cooperation agreement with Shenzhen Jingtai to form a joint venture for an AI-driven drug research platform [4] - Howie Group (00501) intends to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [5] - Singularity Guofeng (01280) enters a GPU distribution cooperation agreement with Muxi Co., aiming to penetrate the domestic AI computing power market [6] - Guorui Life (00108) signs a strategic cooperation memorandum with Mingzhi Medical to promote deep integration and industrial upgrading of "medical + technology + scenarios" [7] Financial Reports - Harbin Electric (01133) anticipates a net profit attributable to shareholders of approximately CNY 2.65 billion for 2025 [8] - Joyson Electronics (00699) expects an annual net profit of about CNY 1.35 billion, representing a year-on-year growth of approximately 40.56% [9] - Guotai Junan International (01788) projects an annual net profit between HKD 1.28 billion and HKD 1.38 billion, a significant increase of 265% to 293% year-on-year [10] - Tianyue Advanced (02631) forecasts annual revenue of CNY 1.45 billion to CNY 1.5 billion [11] - China Power (02380) estimates a consolidated total electricity sales volume of approximately 126 million megawatt-hours for 2025 [12] - Chalco International (02068) expects a total new contract amount of CNY 46.836 billion for 2025, a year-on-year increase of 51.94% [13]

Core Viewpoint - The company has entered into a strategic cooperation memorandum with Mingzhi Medical Technology (Shanghai) Co., Ltd. to integrate core resources using artificial intelligence technology, focusing on real-world research in oncology and innovation in traditional Chinese medicine [1][2] Group 1: Strategic Cooperation - The memorandum aims to promote deep integration and industrial upgrading of "medical + technology + scenarios" [1] - The collaboration will leverage Mingzhi Medical's technological and resource advantages to support the company's transition from traditional property and asset management to a digital AI healthcare service enterprise [1] - Specific cooperation directions include building a digital marketing management system for pharmaceutical companies and a collaborative platform for digital clinical trials [1] Group 2: Business Diversification - The company operates two reportable segments: property management and property development and investment, with operations in China, the United States, and the United Kingdom [2] - The strategic cooperation is expected to enhance the company's financial performance and profitability, aligning with the overall interests of the company and its shareholders [2] - The company is actively seeking business diversification to broaden its revenue sources and improve shareholder returns [2]

Core Viewpoint - The company has signed a strategic cooperation memorandum with Mingzhi Medical Technology (Shanghai) Co., Ltd. to integrate core resources using artificial intelligence technology, focusing on real-world research in oncology and innovation in traditional Chinese medicine [1][2] Group 1: Strategic Cooperation - The cooperation aims to promote the deep integration of "medical + technology + scenarios" and industry upgrades [1] - Specific collaboration directions include the establishment of a digital marketing management system for pharmaceutical companies and a collaborative platform for digital clinical trials [1] - The company plans to leverage its capital market advantages to deepen cooperation with Mingzhi Medical and enhance market promotion through brand effects [1] Group 2: Business Diversification - The company operates two reportable segments: property management and property development and investment, with operations in China, the United States, and the United Kingdom [2] - The strategic cooperation with Mingzhi Medical is expected to facilitate the company's transition from traditional property and asset management to a digital AI healthcare service enterprise, enhancing financial performance and profitability [2] - The initiative aligns with the company's goal of diversifying its business and broadening revenue sources to improve shareholder returns [2]

Core Viewpoint - The company has entered into a strategic cooperation memorandum with Mingzhi Medical Technology (Shanghai) Co., Ltd. to integrate core resources and leverage artificial intelligence technology in the fields of oncology real-world research and traditional Chinese medicine innovation [1][2] Group 1: Strategic Cooperation - The memorandum aims to promote the deep integration of "medical + technology + scenarios" and industry upgrades [1] - The collaboration will focus on building a digital marketing management system for pharmaceutical companies and a collaborative platform for digital clinical trials [1] - The company plans to utilize Mingzhi Medical's technological and resource advantages to transition from traditional property and asset management to a digital AI healthcare service enterprise [1] Group 2: Business Diversification - The company operates in two reportable segments: property management and property development and investment, with operations in China, the United States, and the United Kingdom [2] - The strategic partnership with Mingzhi Medical is expected to enhance the company's financial performance and profitability, aligning with the overall interests of the company and its shareholders [2] - The company is actively seeking business diversification to broaden its revenue sources and improve shareholder returns [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 GR LIFE STYLE COMPANY LIMITED 國銳生活有限公司 （於 香 港 註 冊 成 立 之 有 限 公 司） （股 份 代 號：108） 自願公告 訂立戰略合作備忘錄 本公司董事（「董 事」）會（「董事會」）謹 此 宣 布，於 二 零 二 六 年 一 月 二 十 六 日，本 公司與明智醫療科技（上 海）有限公司（「明智醫療」）訂立了一項戰略合作備忘錄 （「戰略合作備忘錄」）。 根 據 戰 略 合 作 備 忘 錄，本 公 司 與 明 智 醫 療 初 步 同 意 整 合 雙 方 核 心 資 源，以 人 工 智 慧 技 術 為 紐 帶，深 耕 腫 瘤 真 實 世 界 研 究、中 醫 藥 創 新 研 發 領 域，共 同 推 動「醫 療+科 技+場 景」的 深 度 融 合 與 產 業 升 級。本 集 團 擬 借 助 明 智 醫 療 的 技 ...

Group 1 - The insurance sector saw significant gains, with China Life (02628) up 3.81%, China Pacific Insurance (02601) up 2.31%, and Ping An (02318) up 1.17%. Notably, major insurance companies reported a doubling in premium income through bancassurance channels as of January 8, 2026 [1] - The commercial aerospace sector experienced a notable decline, with companies like JunDa Co. (02865) down 7.19% and Asia Pacific Satellite (01045) down 5.94%. This follows a period of intense adjustments and risk warnings from several listed companies in the sector [1] - The real estate sector showed active performance, with companies like R&F Properties (02777) up 4% and Greentown China (03900) up 5.79%. Data from the National Bureau of Statistics indicated a 0.3% month-on-month decline in new residential sales prices in first-tier cities for December 2025, a slight improvement from the previous month [2] Group 2 - HuShang Ayi (02589) reported an expected net profit of 495 million to 525 million RMB for 2025, reflecting a year-on-year growth of 50% to 60% [3] - Yi Communications Group (08031) saw a surge of over 70% upon resuming trading, with a current increase of 53.85%. The company announced a share acquisition deal involving 210 million shares at a price of 0.276 HKD per share, which is a 15.08% discount from the pre-suspension closing price [3] - Guorui Life (00108) experienced an increase of over 11% after announcing a deal to acquire 78.29% of Chunyu Doctor for 269 million RMB, marking its entry into the digital healthcare sector [4]

Company Overview - Guorui Life (00108) has seen a significant increase in stock price, rising by 11.49% to HKD 3.59, with a trading volume of HKD 4.1159 million [1] Acquisition Details - In December 2025, Guorui Life announced the signing of a share transfer agreement to acquire 78.2898% of Chunyu Doctor for a total consideration of RMB 269 million, thus becoming the controlling shareholder [1] - Chunyu Doctor is one of the early internet medical service providers in China, with a service network covering over 300 cities and having served more than 400 million users [1] Business Model - Chunyu Doctor has developed a comprehensive service system that includes online consultation, AI diagnosis, offline treatment, and health management [1] Industry Insights - The internet medical industry is currently experiencing rapid growth, with a market size exceeding RMB 100 billion and an annual growth rate of over 18% [1] - The primary user demographic consists of middle-aged and young individuals [1] - National policies are increasingly supportive of the industry, including the relaxation of treatment scopes and inclusion in health insurance, promoting innovation and standardized development [1] - The industry is driven by technologies such as mobile internet, big data, artificial intelligence, and 5G, with a competitive landscape characterized by leading enterprises and innovative niche markets [1]